Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Fungal Infection Reports
Erschienen in: Current Fungal Infection Reports 2/2016

12.04.2016 | Clinical Mycology Lab Issues (K Lagrou, Section Editor)

Evolution of Cryptococcal Antigen Testing: What Is New?

verfasst von: Elizabeth Nalintya, Reuben Kiggundu, David Meya

Erschienen in: Current Fungal Infection Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Over the last decade, an upsurge in both the frequency and severity of fungal infections due to the HIV/AIDS epidemic and the use of immunosuppressive therapy has occurred. Even diagnostic methods like culture and microscopy, which have low sensitivity and longer turnaround times, are not widely available, leading to delays in timely antifungal therapy and detrimental patient outcomes. The evolution of cryptococcal antigen (CrAg) testing to develop inexpensive and more sensitive methods to detect cryptococcal antigen is significant. These newer tests employ immunoassays as part of point-of-care platforms, which do not require complex laboratory infrastructure, and they have the potential to detect early disease and reduce time to diagnosis of cryptococcal infection. Advocacy for widely available and efficacious life-saving antifungal treatment should be the only remaining challenge.
Literatur
1.•
2.
Pyrgos V et al. Epidemiology of cryptococcal meningitis in the US: 1997–2009. 2013.
3.
Park BJ et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30.CrossRefPubMed
4.•
Marcos JY, Pincus DH. Fungal diagnostics: review of commercially available methods, in fungal diagnostics. Berlin: Springer; 2013. p. 25–54. A review of diagnostic methods available on the market.CrossRef
5.
Lui G et al. Cryptococcosis in apparently immunocompetent patients. QJM Int J Med. 2006;99(3):143–51.CrossRef
6.
7.
Hakim JG et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS. 2000;14(10):1401–7.CrossRefPubMed
8.
Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 2006;20(3):507–44.CrossRef
9.
Morgan J et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002–2004. Clin Infect Dis. 2006;43(8):1077–80.CrossRefPubMed
10.
Passoni LFC. Wood, animals and human beings as reservoirs for human Cryptococcus neoformans infection. Rev Iberoam Micol. 1999;16(6):77–81.
11.
Colom VM et al. Isolation of Cryptococcus neoformans from environmental samples in Alicante. Rev Iberoam Micol. 1997;14(2):63–4.
12.
Rolston KV. Editorial commentary: cryptococcosis due to Cryptococcus gattii. Clin Infect Dis. 2013;57(4):552–4.CrossRefPubMed
13.
Stephen C et al. British Columbia: multispecies outbreak of cryptococcosis on Southern Vancouver Island, British Columbia. Can Vet J. 2002;43(10):792.PubMedPubMedCentral
14.
Bartlett KH et al. A decade of experience: Cryptococcus gattii in British Columbia. Mycopathologia. 2012;173(5–6):311–9.CrossRefPubMed
15.
Chen S et al. Epidemiology and host-and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis. 2000;31(2):499–508.CrossRefPubMed
16.
Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovirol. 2002;8(3):158–67.CrossRefPubMed
17.
Perfect JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322.CrossRefPubMed
18.
19.
Holmes CB et al. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis. 2003;36(5):652–62.CrossRefPubMed
20.
Gordon SB et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis. 2000;31(1):53–7.CrossRefPubMed
21.
Békondi C et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis. 2006;10(5):387–95.CrossRefPubMed
22.
Okongo M et al. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol. 1998;27(4):698–702.CrossRefPubMed
23.
Corbett EL et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis. 2002;34(9):1251–8.CrossRefPubMed
24.
Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis. 1997;176(3):632–6.CrossRefPubMed
25.
Hajjeh RA et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis. 1999;179(2):449–54.CrossRefPubMed
26.
Mirza SA et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. Clin Infect Dis. 2003;36(6):789–94.CrossRefPubMed
27.
Kaplan JE et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Supplement 1):S5–14.CrossRefPubMed
28.
Pappas PG et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33(5):690–9.CrossRefPubMed
29.
Staib F. Cyptococcus neoformans und Guizotia abyssinica (syn. G. oleifera DC). Z Hyg Infekt Med Mikrobiol Immunol Virol. 1962;148(5):466–75.
30.
Fleming W, Hopkins J, Land G. New culture medium for the presumptive identification of Candida albicans and Cryptococcus neoformans. J Clin Microbiol. 1977;5(2):236–43.PubMedPubMedCentral
31.
32.••
Boulware DR et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014;20(1):45. Recently published work on new techniques.CrossRefPubMedPubMedCentral
33.
Chandler FW, Kaplan W and Ajello L Color atlas and text of the histopathology of mycotic diseases 1980: Year Book Medical Publishers.
34.
Monheit J, Cowan D, Moore D. Rapid detection of fungi in tissues using Calcofluor white and fluorescence microscopy. Arch Pathol Lab Med. 1984;108(8):616–8.PubMed
35.
Bloomfield N, Gordon MA, Elmendorf DF. Detection of Cryptococcus neoformans antigen in body fluids by latex particle agglutination. Exp Biol Med. 1963;114(1):64–7.CrossRef
36.
Gates-Hollingsworth MA, Kozel TR. Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen. Clin Vaccine Immunol. 2013;20(4):634–5.CrossRefPubMedPubMedCentral
37.••
Hansen J et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol. 2013;20(1):52–5. Ground breaking research on a new rapid test (LFA).CrossRefPubMedPubMedCentral
38.•
Binnicker M et al. A comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012; CVI. 00446–12. A comparison study of testing techniques.
39.•
Qin Z et al. Significantly improved analytical sensitivity of lateral flow immunoassays by using thermal contrast. Angew Chem. 2012;124(18):4434–7. Research on improvement of LFA test.CrossRef
40.
Morawski BM, BD, Nalintya E, Kiragga A, Kakooza F, Rajasingham R, Park BJ et al. Pre-ART cryptococcal antigen titer associated with preemptive fluconazole failure. Conference on Retroviruses and Opportunistic Infections (CROI). 2016. Abstract # 16–227.
41.
Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and preemptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012;59(5):85.CrossRefPubMedCentral
42.
Jarvis JN et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Phys AIDS Care (JIAPAC). 2012;1545109712459077.
43.
Organization WH Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. 2011.
44.
Mfinanga S et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385(9983):2173–82.CrossRefPubMed
45.
Longley N et al. Cryptococcal antigen screening in patients initiating ART in South Africa: a prospective cohort study. Clin Infect Dis. 2015; civ936.
46.
Kapoor SW et al. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia. AIDS. 2015;29(18):2473–8.PubMed
Metadaten
Titel
Evolution of Cryptococcal Antigen Testing: What Is New?
verfasst von
Elizabeth Nalintya
Reuben Kiggundu
David Meya
Publikationsdatum
12.04.2016
Verlag
Springer US
Erschienen in
Current Fungal Infection Reports / Ausgabe 2/2016
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-016-0256-3

Weitere Artikel der Ausgabe 2/2016

Current Fungal Infection Reports 2/2016 Zur Ausgabe

Current Management of Fungal Infections (RE Lewis, Section Editor)

Improved Radiographic Imaging of Invasive Fungal Disease: The Cornerstone to Antifungal Stewardship in the Hematology Units?

Clinical Mycology Lab Issues (K Lagrou, Section Editor)

Next-Generation Sequencing in the Mycology Lab

Clinical Mycology Lab Issues (K Lagrou, Section Editor)

Therapeutic Drug Monitoring of Posaconazole: an Update

Clinical Mycology Lab Issues (K Lagrou, Section Editor)

Point of Care Testing for the Diagnosis of Fungal Infections: Are We There Yet?

Current Management of Fungal Infections (RE Lewis, Section Editor)

Impact of New Diagnostic Approaches for Invasive Candidiasis on Antifungal Stewardship

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise